<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01631201</url>
  </required_header>
  <id_info>
    <org_study_id>APL-1648-027</org_study_id>
    <nct_id>NCT01631201</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Rifalazil for the Treatment of Chlamydia Trachomatis Infection in Women</brief_title>
  <official_title>A Phase 2b, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Safety and Efficacy of Rifalazil (25 Milligram) Compared With Azithromycin (1 Gram) for the Treatment of Uncomplicated Genital Chlamydia Trachomatis Infection in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ActivBiotics Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ActivBiotics Pharma, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety and effectiveness of an investigational antibiotic drug,
      rifalazil for the treatment of uncomplicated genital Chlamydia trachomatis infection. This
      study will examine the effects of 25 milligram of rifalazil compared with azithromycin 1
      gram, which will be given as a single dose to women who have genital chlamydial infection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with microbiologic cure of chlamydia trachomatis infection at Day 22</measure>
    <time_frame>Day 22</time_frame>
    <description>Microbiologic test result will be reported as positive or negative for chlamydia trachomatis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with microbiologic cure of chlamydia trachomatis infection at Day 36.</measure>
    <time_frame>Day 36</time_frame>
    <description>Microbiologic test result will be reported as positive or negative for chlamydia trachomatis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing adverse events in the two treatment groups.</measure>
    <time_frame>Day 36 (end of study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing clinically significant laboratory abnormalities in the two treatment groups.</measure>
    <time_frame>Day 36 (end of study)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Chlamydia Trachomatis Infection</condition>
  <arm_group>
    <arm_group_label>Rifalazil 25 milligram</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin 1 gram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of Azithromycin 1 gram to be administered on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifalazil 25 milligram</intervention_name>
    <description>Single dose of 25 milligram rifalazil to be administered on Day 1.</description>
    <arm_group_label>Rifalazil 25 milligram</arm_group_label>
    <other_name>KRM-1648</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin 1 gram</intervention_name>
    <description>Single dose of Azithromycin 1 gram to be administered on Day 1.</description>
    <arm_group_label>Azithromycin 1 gram</arm_group_label>
    <other_name>Zithromax</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female â‰¥ 19 years old diagnosed with genital chlamydia trachomatis infection.

          -  Use an effective method of contraception.

          -  Agree to be abstinent or to have partners use condoms for all sexual activities during
             the study.

        Exclusion Criteria:

          -  Subject or sexual partner is known to have gonorrhea.

          -  History of repeated chlamydia trachomatis infection.

          -  HIV, syphilis, or active Hepatitis B or C infection.

          -  Treatment with antimicrobial therapy with known activity against chlamydia trachomatis
             within 4 weeks of enrollment.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chalom B Sayada, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>ActivBiotics Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23456</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2012</study_first_submitted>
  <study_first_submitted_qc>June 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2012</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chlamydia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Chlamydia Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>KRM 1648</mesh_term>
    <mesh_term>Rifamycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

